Research Highlight: Study on COVID‑19 in Children With Neuromuscular Disorders
Study from the Neuromuscular Working Group of the Spanish Pediatric Neurology Society
The NMD4C would like to highlight a paper from the Neuromuscular Working Group of the Spanish Pediatric Neurology Society, who have recently published a study which aims to describe the clinical characteristics and outcome of COVID-19 in the pediatric NMD patient population.
The most prevalent NMD in the study were SMA type 1 and 2 (including patients undergoing treatment with nusinersen, risdiplam or salbutamol), and Duchenne Muscular Dystrophy (including patients undergoing treatment with deflazacort), along with several other neuromuscular conditions.
Although derived from a small sample size, the study’s conclusions suggest that the course of COVID-19 in pediatric NMD populations may not be as severe as expected, due to the mitigating role of young age compared to risk factors including decreased respiratory capacity or a weak cough.
The NMD4C hopes to see further studies published which examine the impact of the COVID-19 virus across both adult and pediatric NMD populations to further our knowledge of its impact within our community.
Read the full article here
Read next...
Applications Open for New NMD4C Collaborative Research Training Awards!
The NMD4C is excited to announce a new program for neuromuscular research trainees that will support collaboration opportunities between Canadian research labs.
NMD4C Members Receive Dr David Green Awards from Muscular Dystrophy Canada
We are excited to share that several NMD4C investigators and members have been honored with a Dr David Green Award from Muscular Dystrophy Canada!
Lower Extremity Muscle Strengthening Program in Myotonic Dystrophy Type 1 from Groupe de recherche interdisciplinaire sur les maladies neuromusculaires
The Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) recently created a video aimed at health professionals that provides an in-depth explanation of the Myotonic dystrophy (DM1) training parameters used in their studies.
Fifth Annual Clinical Fellowship Competition from NMD4C and MDC Opens May 1st
The NMD4C and MDC clinical neuromuscular fellowship competition is accepting applications for the 2026 competition until June 12, 2025.
